skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Your views on AMGN. The price is moving in the range between US$230 to US$245. Pays a dividend yielding 2.5% plus and increasing dividend year over year. One bad thing is happening with its new drugs. They are failing and not getting approval. Your views. Should exit the position? What's your choice? Do not own any drug company but own BAX-N as 10% of my portfolio. I run very concentrated portfolio based on individual companies and ignoring sectors.
Read Answer Asked by Piyush on June 08, 2021
Q: HI Gang

I have a happy problem....BNTX is growing exponentially. I sold some of my shares one month ago and cannot decide whether I should shave a few more off. My weighting is 2.85% again. (But I have 65 stocks - still trying to reduce this). If I were to own only 25 or so stocks my weighting would be over 8%. How should I think of proceeding?
Thank you and stay safe...we are hopefully closing in on the finish line.
Read Answer Asked by El-ann on June 07, 2021
Q: I am looking to increase my healthcare exposure in the US. Would you recommend VEEV or GH or both or would you have other recommendations. Risk is not a factor.
Thanks for your service!
Read Answer Asked by Ozzie on June 02, 2021
Q: Hi Peter, I've taken some comfort despite my loss on BDX shares because some commentators have pointed out that their products (joint replacements) will soon benefit from the pent-up demand due to Covid-caused delays in such surgeries. However, Stryker, which is in a similar business, has significantly outperformed BDX both before and after Covid. In other words, do you know why BDX is so underperforming SYK, and would you hang onto (or perhaps add to) BDX at this point? Thank you.
Read Answer Asked by James on June 02, 2021
Q: Regarding todays nr, is it safe to assume the observations from the clinical trial are in a positive light? I have a small position and am considering adding - since the casino is closed. London, Ontario-TheNewswire -June 1, 2021 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF)(FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce that lead principal investigator Dr. Piotr Witkowski and the Clinical Trial Investigator Team for its US Phase I/II Type 1 Diabetes clinical trial will present data and observations from the ongoing study in a presentation at the upcoming American Transplant Congress (ATC) Virtual Connect to be held June 4 - 9, 2021.
Read Answer Asked by Charles on June 01, 2021
Q: I just saw the latest short report. WELL had over 5 million listed which is a ton. Very few are higher. Is there market rules which forces them to cover where they have no choice. Could a Game Stop Corp scenario happen.

Thanks Steve
Read Answer Asked by Steve on May 31, 2021
Q: Eddy Elfenbein recently wrote a detailed review of Veeva Systems (he also did one on The Trade Desk a few weeks ago for those that want to better understand that company). In general, he likes the company and its prospects but felt it was quite overpriced. I know that many tech growth stocks have seen share price reductions and Veev seems in line with those drops. I have owned the stock for a while and intend to continue to own it. What do you think my expectations should be going forward - slow and steady growth, high growth or it flatlines for several months as it grows into its current valuation?

Appreciate your insight.

Paul F.
Read Answer Asked by Paul on May 28, 2021
Q: Is Merk unjustifiably cheap or is it a value trap? Which of MRK, JNJ, MDT (or other suggestion) would you recommend as a buy and forget cornerstone healthcare holding for someone looking for long term capital appreciation and dividend growth. My only other healthcare position is ABBV. Please also explain the rationale. Thank you!
Read Answer Asked by Matthew on May 27, 2021
Q: I have held this healthcare ETF for a couple years, and added some more in the market mayhem last year. It pays a healthy dividend and I have some capital gains. Relative to the fund's market cap my shares are of course insignificant, however, it seems to be a light trader and I have noticed that on several days my holdings exceed the daily trading volume. Should I be concerned about this? Would it make any sense to sell part or all and move the funds into a similar ETF like HHL (or any others you might suggest)?
Thank-you
Read Answer Asked by grant on May 27, 2021
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!